SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-170124
Filing Date
2023-06-20
Accepted
2023-06-20 16:06:02
Documents
12
Period of Report
2023-06-14
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d465222d8k.htm   iXBRL 8-K 33412
  Complete submission text file 0001193125-23-170124.txt   155056

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20230614.xsd EX-101.SCH 2835
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20230614_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20230614_pre.xml EX-101.PRE 11251
6 EXTRACTED XBRL INSTANCE DOCUMENT d465222d8k_htm.xml XML 3370
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 231025059
SIC: 2834 Pharmaceutical Preparations